Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients

Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy

A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed after 1 to 3 years of antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 3 years. Patients will be assessed at baseline and at every six months for blood count, liver function test, alpha fetoprotein (AFP), prothrombin time, liver ultrasonography, liver stiffness measurement (LSM), Hepatitis B virus (HBV) DNA and HBV serological markers. HBV-related endpoint events, including cirrhosis decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), hepatocellular carcinoma (HCC), liver transplantation and liver-related death, will be collected during follow-up.

Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients

Recruitment

Summary

Participation Requirements

Description

Tracking Information